Navigation Links
World Leaders in Alzheimer’s Innovation to Discuss Progress, Collaboration at DIA Annual Meeting
Date:6/17/2013

Horsham, Pa. (PRWEB) June 17, 2013

Without treatment, experts say, the number of Alzheimer’s disease patients worldwide is expected to almost double by 2025 to 34 million people—a startling realization that’s driving global forces to join together to advance research for the debilitating disease before it’s too late.

A number of innovative initiatives hold hope for a promising future in understanding Alzheimer’s, including new ways to implement genome sequencing in research, focus on much-needed support for caregivers and look for novel methods to improve clinical trials. These breakthrough efforts will be discussed on June 26 by U.S. leaders in Alzheimer’s research and regulation in three Advancing Alzheimer’s Innovation sessions at the DIA 2013 49th Annual Meeting at the Boston Convention & Exhibition Center.

Scientists are now focusing on the interaction of gender, genetic risk factors and biological markers of the disease. Harvard Medical School professors Dr. Rudy Tanzi, director of the Genetics and Aging Research Unit of the MassGeneral Institute for Neurodegenerative Disease and recently profiled by The Boston Globe and cited as a “rock star of science” by GQ, and Dr. Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, will join a panel of experts discussing collaboration to support research at Advancing Alzheimer’s Innovation: A Call to Action.

Tanzi, leader of the Whole Genome Sequencing Project, aims to propel research to identify the genetic risk for Alzheimer’s disease—a vital step in discovering a therapy.

“We are taking advantage of cutting-edge technology to discover exactly how our genes determine susceptibility to Alzheimer’s disease,” Tanzi said. “This panel will discuss how this key knowledge will pioneer novel drug discovery efforts and pave the future of Alzheimer’s research.”

Sperling is the principal investigator for the first-ever clinical trial aimed at older people who are at genetic risk of developing Alzheimer’s, but who have yet to show symptoms. Sperling will discuss the new era of prevention trials and the importance of studying the role gender may play in developing the disease. The three-year-long clinical trial, launching in November, will be made up of 1,000 older individuals and is funded jointly by the National Institutes of Health and Eli Lilly.

“It is critical to understand the interaction of risk factors and biological markers of disease pathology as we move forward with the trial,” Sperling said.

Adding to the discussion about innovative approaches to treating Alzheimer’s, Dr. Nicholas Kozauer, clinical lead for the Food and Drug Administration’s Division of Neurology Products, will address the need for a regulatory framework for pre-dementia clinical trials. In March, Kozauer published a compelling piece in the New England Journal of Medicine on the need for innovative approaches in trial design and selection as the drug-development community turns its sights on the early stages of the disease.

The session is chaired by Meryl Comer, president of the Geoffrey Beene Foundation Alzheimer’s Initiative, which just launched a $100,000 Global NeuroDiscovery Challenge to look at gender-based differences in Alzheimer’s. George Vradenburg, chairman of USAgainstAlzheimer’s, will discuss plans to use the G-8 to develop an international approach to address Alzheimer’s and dementia.

Below are the two other June 26 sessions focused on Alzheimer’s treatment and care:

Advancing Alzheimer’s Innovation: Patient Advocacy, Caregiver Support and Health Care System Impact at 1:45 p.m.

New initiatives are responding to the growing stress on caregivers and the need to help individuals remain independent for as long as possible. Robert Feeney, senior director of evidence-based reimbursement for Sanofi, will lead a panel of experts discussing the initiatives that prepare society for the proper care of Alzheimer’s patients and caregivers. The forum will address best practices in delivery of care, whether in institutions or at home.

Advancing Alzheimer’s Innovation: Clinical Development Successes and Challenges at 4 p.m.

Only about 8 percent of drugs that treat diseases—including Alzheimer’s—affecting the central nervous system enter clinical trials and the U.S. market. Innovative approaches to clinical design are needed to advance the success rate of drugs that treat Alzheimer’s. Sperling, discussing the current landscape of Alzheimer’s clinical trials and lessons learned from past trials, will join executives from Eisai Inc., and Merck & Co., to address the challenges encountered in clinical development and recommendations in design to improve the success of clinical trials.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at http://www.diahome.org and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.

###

Read the full story at http://www.prweb.com/releases/2013/6/prweb10841624.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology
2. Measles Deaths Falling Worldwide
3. Surprising results for use of dialysis for kidney failure in developing world
4. Blond Genes May Vary Around the World
5. Infection Causes 1 in 6 Cancers Worldwide: Study
6. New initiative aims to increase mobility for disabled children worldwide
7. World Health Assembly endorses new plan to increase global access to vaccines
8. People Who Lived Near World Trade Center Report More Lung Disease
9. After 25 years, World No Tobacco Day is making an impact
10. Brave New World of Genetics Requires Safeguards, Experts Say
11. UICC World Cancer Congress -- Aug. 27-30, 2012 -- Montreal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... America (UCAOA) and College of Urgent Care Medicine will host industry leaders for ... and speakers will help those in the industry adapt to the issues currently ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... EAST HANOVER, N.J. , April 19, 2017 ... study conducted by the National Heart, Lung, and ... Health (NIH) demonstrating that 58% of patients with ... at six months when treated with eltrombopag at ... treatment 1 . The study evaluated three sequential ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology: